Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05338762 · ClinicalTrials.gov registry record
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
A clinical trial of SARS CoV 2 Infection, sponsored by MiCo BioMed Co..
- Completed
- Registry status
- 218
- Enrollment target
- 5
- Study locations
NCT05338762: Completed study of SARS CoV 2 Infection, sponsored by MiCo BioMed Co..
NCT05338762 is a study of SARS CoV 2 Infection that has completed, run by MiCo BioMed Co.. The registered enrollment target is 218 participants, below the 4,181-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05338762, a study of SARS CoV 2 Infection, has completed, sponsored by MiCo BioMed Co..
- COMPLETED
- Registry status
- 218 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test. When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.
Primary Outcome
1. PPA (Sensitivity) between ≥87% with a lower bound of the 95% confidence interval greater than 74.4% 2. NPA (Specificity) ≥ 93% with a lower bound of the 95% confidence interval greater than 87.8%
Conditions Studied
Study Locations (5)
Ohio
- WellNow Urgent Care - Cincinnati
- WellNow Urgent Care - Columbus
- WellNow Urgent Care - Dayton
Mississippi
- Mississippi State University - Starkville
New Jersey
- Joy Internal Medicine - Englewood Cliffs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-08-03 |
What the finished NCT05338762 record still lists
NCT05338762 is an observational study that tracks outcomes without assigning an intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 4,181-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (95% lower).
The record links to 1 condition, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 0 interventions.
NCT05338762 lists 5 locations in 3 states (Ohio, Mississippi, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05338762 about?
NCT05338762 is a clinical study titled "TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood". The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test. ...
What is the current status of trial NCT05338762?
This trial is currently completed. The enrollment target is 218 participants. The study started on 2021-06-02. Estimated completion is 2022-08-03.
What conditions does trial NCT05338762 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection.
Who is sponsoring clinical trial NCT05338762?
This trial is sponsored by MiCo BioMed Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05338762 being conducted?
This trial has 5 study locations across Mississippi, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05338762's enrollment target sits among peer trials
218 26th of 35 higher than 10 of 35 other SARS CoV 2 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
-
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
RECRUITING · Phase 2
-
COVID-19 Transmission and Morbidity in Malawi
RECRUITING
-
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI